Literature DB >> 8806654

Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence.

Z A Pramono1, Y Takeshima, H Alimsardjono, A Ishii, S Takeda, M Matsuo.   

Abstract

In this paper we first report that exon skipping from the dystrophin gene transcript could be induced in living cells by an antisense oligodeoxynucleotide (ODN) complementary to an exon recognition sequence (ERS). Incubation of lymphoblastoid cells with an antisense ODN against the purine-rich region of dystrophin exon 19 resulted in skipping of the exon from the dystrophin transcript. Skipping of exon 19 started to appear after 6 hours of incubation, and complete skipping was observed after 24 hours of incubation. None of the other 78 dystrophin exons were skipped, and exon 19 skipping could be induced by the sense ODN or by an antisense ODN corresponding to another ERS. These results showed that antisense ODN against ERS can induce exon skipping even in living cells and ERS is functioning as an essential cis-element for proper splicing in dystrophin pre-mRNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806654     DOI: 10.1006/bbrc.1996.1375

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  36 in total

Review 1.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

Review 2.  Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy.

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

Review 3.  Dystrophin-deficient large animal models: translational research and exon skipping.

Authors:  Xinran Yu; Bo Bao; Yusuke Echigoya; Toshifumi Yokota
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

4.  Rational design of antisense oligomers to induce dystrophin exon skipping.

Authors:  Chalermchai Mitrpant; Abbie M Adams; Penny L Meloni; Francesco Muntoni; Sue Fletcher; Steve D Wilton
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

5.  Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

Authors:  Takehiko Shiraishi; Jonhard Eysturskarth; Peter E Nielsen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

6.  Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.

Authors:  Takashi Saito; Akinori Nakamura; Yoshitsugu Aoki; Toshifumi Yokota; Takashi Okada; Makiko Osawa; Shin'ichi Takeda
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

7.  Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.

Authors:  Toshifumi Yokota; Akinori Nakamura; Tetsuya Nagata; Takashi Saito; Masanori Kobayashi; Yoshitsugu Aoki; Yusuke Echigoya; Terence Partridge; Eric P Hoffman; Shin'ichi Takeda
Journal:  Nucleic Acid Ther       Date:  2012-08-13       Impact factor: 5.486

8.  Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.

Authors:  Damian Ittig; Songkai Liu; Dorte Renneberg; Daniel Schümperli; Christian J Leumann
Journal:  Nucleic Acids Res       Date:  2004-01-15       Impact factor: 16.971

9.  Can Wharton jelly derived or adipose tissue derived mesenchymal stem cell can be a treatment option for duchenne muscular dystrophy? Answers as transcriptomic aspect.

Authors:  Eda Sun; Erdal Karaoz
Journal:  Am J Stem Cells       Date:  2020-08-25

10.  Genetic correction of splice site mutation in purified and enriched myoblasts isolated from mdx5cv mice.

Authors:  Katie Maguire; Takayuki Suzuki; Darlise DiMatteo; Hetal Parekh-Olmedo; Eric Kmiec
Journal:  BMC Mol Biol       Date:  2009-02-23       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.